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Abstract
Endometriosis is considered as a benign aseptic inflammatory disease, characterised by the presence of ectopic
endometrium-like tissue. Its symptoms (mostly pain and infertility) are reported as constant stressors. Corticotropin
releasing hormone (CRH) and urocortin (UCN) are neuropeptides, strongly related to stress and inflammation. The effects of
CRH and UCN are mediated through CRHR1 and CRHR2 receptors which are implicated in several reproductive functions
acting as inflammatory components. However, the involvement of these molecules to endometriosis remains unknown. The
aim of this study was to examine the expression of CRHR1 and CRHR2 in endometriotic sites and to compare the expression
of CRHR1 and CRHR2 in eutopic endometrium of endometriotic women to that of healthy women. We further compared the
expression of CRH, UCN, CRHR1 and CRHR2 in ectopic endometrium to that in eutopic endometrium of women with
endometriosis. Endometrial biopsy specimens were taken from healthy women (10 patients) and endometrial and
endometriotic biopsy specimens were taken from women with endometriosis (16 patients). The expression of CRH, UCN,
CRHR1, and CRHR2 was tested via RT-PCR, immunohistochemistry and Western blotting. This study shows for the first time
that CRH and UCN receptor subtypes CRHR1b and CRHR2a are expressed in endometriotic sites and that they are more
strongly expressed (p,0.01) in eutopic endometrium of women with endometriosis compared to healthy women
endometrium at the mRNA and protein level. CRH, UCN, CRHR1 and CRHR2 mRNA were also more highly expressed in
ectopic rather than eutopic endometrium (CRH, UCN, CRHR2a: p,0.01, CRHR1b: p,0.05) and protein (CRH and UCN:
p,0.05, CRHR1 and CRHR2: p,0.01) in women with endometriosis. These data indicate that CRH and UCN might play an
immunoregulatory role in endometriotic sites by affecting reproductive functions such as decidualization and implantation
of women with endometriosis.
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Introduction
Endometriosis is one of the most important benign chronic
diseases affecting the 6–10% of women of reproductive age, being
mainly associated with pelvic pain, adhesion formation and
infertility. Endometriosis is characterised by the ectopic presence
of endometrial stroma and epithelium [1,2]. Although its
pathogenesis is still unclear, endometriosis has been proven to be
both an estrogen-dependent and a chronic inflammatory disease
[3,4]. In that context, endocrine/paracrine influences and
immunological aspects have been investigated. Thus, several
growth factors, cytokines, immune cells and hormones in eutopic
and ectopic endometrium, are considered to be involved in the
pathophysiology of endometriosis-related infertility [5].
CRH (Corticotropin Releasing Hormone) is a 41-amino acid
neuropeptide, synthesised in the hypothalamus, regulating the
hypothalamus-pituitary-adrenal axis [6,7]. CRH expression and
biological functions are mediated by its membrane receptors,
CRH-R1 (a, b, c, c-h) and CRH-R2 (a, b, c) [8,9,10]. CRH
receptors are also activated by other endogenous agonists, such as
urocortin (UCN), which is a 40-amino acid peptide belonging to
the corticotropin-releasing hormone family and is structurally
related to CRH [11,12]. Apart from the central nervous system,
CRH and its receptors are expressed in several sites of the female
reproductive system, including the endometrial glands, decidua-
lized stroma, trophoblast, syncytiotrophoblast and placental de-
cidua [13,14]. Moreover, CRH and UCN are secreted at
inflammatory sites, acting as proinflammatory factors. Reproduc-
tive CRH has been shown to serve as an autocrine and paracrine
modulator and to participate in decidualization, embryo implan-
tation and maintenance of human pregnancy [15–24]. In addition,
CRH and UCN mRNA have been found to be expressed by
endometriotic cells, while endometriotic lesions show a strongly
positive staining reaction for CRH and UCN [25]. The expression
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and function of CRH and UCN have also been found to be
impaired in eutopic endometrium of women with endometriosis
[26]. These data suggest a crucial role of CRH and UCN in
pathogenesis of endometriosis. However, the relative expression of
CRH, UCN and their receptors in eutopic and ectopic endome-
trium of endometriotic women and in eutopic endometrium of
healthy women and women with endometriosis has never been
investigated. Additionally, CRH receptors and in particular their
subtypes have never been identified in endometriotic lesions. In
the current study, we have investigated the relative expression
levels of these molecules in eutopic and ectopic endometrium of
endometriotic and healthy women providing the first evidence for
a potential role of CRH receptors in infertility profile of
endometriotic women.
The aim of this study was i) to examine the expression of CRH,
UCN, CRHR1, CRHR2 and their subtypes CRHR1b and
CRHR2a at endometriotic sites, ii) to compare the expression of
those receptor in eutopic endometrium of endometriotic and
healthy women and iii) to evaluate and compare the expression of
CRH, UCN and their receptors in endometriotic sites with those
in eutopic endometrium of endometriotic women.
Materials and Methods
Tissue Sample Collection
Endometrial biopsy specimens (at secretory phase, as it was
confirmed by the progesterone levels of the women) were taken
from healthy women (10 patients) undergoing hysteroscopy for
diagnostic reasons as their most recent menstrual cycles were
characterised by spontaneous spotting haemorrhage. The out-
come of their hysteroscopy showed that they were all healthy
apart from 3/10 having small polyps. Endometrial and
Endometriotic tissue biopsies (stage III and IV) at secretory
phase, as it was confirmed by the progesterone levels of the
patients, were obtained from 16 patients diagnosed with
endometriosis on different sites (peritoneal nodule, rectovaginal
nodule, rectouterine nodule, right and left ovarian cyst
endometriosis, left and right uterosacral legiment nodule),
sharing all the same pathology, in the Department of Obstetrics
and Gynaecology, St Bartholomew’s Hospital of Queen Mary
University, London, UK (Research Ethics Committee Reference
Number: 05/Q0604/44). This research protocol was approved
by the Ethics Committee of Queen Mary University, London,
UK. All participants provided their written informed consent to
participate. It is important to notice that the most critical
reproductive hormone levels of both healthy and endometriotic
patients did not affect the outcome of our research protocols as
they ranged among: FSH levels (day 3 of the menstrual cycle):
healthy patients 6–8 mlU/ml, endometriotic patients 7–9 mlU/
ml, E2 levels (day 3 of the menstrual cycle): healthy patients
4567 pg/ml, endometriotic patients 50611 pg/ml and Pro-
gesterone levels (day 21 of the menstrual cycle): healthy patients
1762 ng/ml, endometriotic patients 1563 ng/ml.
Tissue Homogenisation - RNA Extraction- cDNA Synthesis
RNA was isolated from frozen endometrium of healthy women
(10 patients). Eutopic endometrium and endometriotic tissue
samples from 16 patients with endometriosis were homogenised in
Trizol (Invitrogen, Carlsbad, USA). RNA was measured in
a spectrophotometer by measuring ultraviolet absorbance at
260 nm and used for the cDNA synthesis according to the cDNA
synthesis Kit (Thermoscript, Invitrogen, Carlsbad, USA).
RT-PCR Detection of CRH, UCN, CRHR1b and CRHR2a
To quantify mRNA expression of CRHR1b and CRHR2a in
eutopic endometrium of healthy and endometriotic women and
CRH and UCN in endometrium and endometriotic tissue from 16
patients, reverse transcription PCR (RT-PCR) of CRH, UCN,
CRHR1b and CRHR2a. was performed. Ten microliters of the
amplification products (CRH: 413 bp, UCN: 146 bp,
CRHR1b:554 bps, CRHR2a:322 bps) was separated on a 2%
agarose gel and visualized by ethidium bromide staining. Human
CRH primer sequences were as follows: Forward: 59- CAC CCT
CAG CCC TTG GAT TTC -39, Reverse: 59- GCC CTG GCC
ATT TCC AAG AC -39. UCN primer sequences were as follows:
Forward: 59- CAG GCG AGC GGC CGC G-39, Reverse: 59-
CTT GCC CAC CGA GTC GAA T-39. CRHR1b primer
sequences were as follows: Forward: 59- ATG GAC GCG GCA
CTG CTC CA-39, Reverse: 59 – CAC GGC CTC TCC ACG
AGG G-39. CRHR2a primer sequences were as follows: Forward:
59- GGC CAG GCT GCA CCC ATT G-39, Reverse: 59- TCG
CAG GCA CCG GAT GCT C-39. All primers were provided by
VBC Biotech, Vienna, Austria. Placenta and myometrium
homogenated total RNA was used as positive controls and
GAPDH (primers for GAPDH were: forward: 59-GCCA-
CATCGCTCAGACACCA-39and reverse: 59-GAT-
GACCCTTTTGGCTCCCC-39) as a house keeping gene. Band
intensities of mRNA of interest were normalized with band
intensities of GAPDH and expressed as arbitrary units (a.u.).
Immunohistochemical Analysis
Formalin-fixed, paraffin-embedded tissue sections (4 mm thick)
of eutopic and ectopic endometrium from 16 patients were
deparaffinized in xylene and rehydrated through graded concen-
trations of ethanol. Antigen retrieval (350 W, 3 cycles, 5 min each
in citrate buffer: 10% citric acid mix –9 ml citric acid and 41 ml
sodium citrate in 450 ml ddH20) was followed. After inhibition of
endogenous peroxidases with 3% H2O2 (5 min), unspecific
antibody binding was blocked with 10% power block (BioGenex
Lig DAB substrate Pack, BioGenex Laboratories Inc, Fremont,
CA, USA) for 10 min. Serial sections were then incubated with
primary antibodies against human CRH (1:200, H-019-06, Rabbit
Anti-Corticotropin Releasing Factor, Phoenix Pharmaceuticals,
Belmont, USA) or UCN (1:200, H-019-14, Rabbit Anti-Urocortin
Serum, Phoenix Pharmaceuticals, Belmont, USA), overnight at
4uC. Both blocking as well as detection and visualization of
staining were performed by using the BioGenex Supersensitive
link-label Detection System (BioGenex Laboratories Inc, Fremont,
CA, USA) followed by the BioGenex Lig DAB substrate Pack
(BioGenex Laboratories Inc, Fremont, CA, USA), according to the
manufacturer’s protocols. Finally the slides were counterstained
with Mayer’s heamatoxylin (Dako, Carpinteria, CA, USA) for
3 min, washed in tap water and covered using Glycergel (Dako,
Carpinteria, CA, USA). Negative controls were performed by
replacing the primary antibody with normal rabbit or goat IgG as
isotype control and placental tissue was used as negative tissue
control. The sections were examined by light microscopy. The
intensity and distribution of the staining reaction were evaluated
by two blinded, independent observers, including a gynaecological
pathologist, using the semiquantitative immunoreactive score
(IRS). The IRS was calculated by multiplication of optical staining
intensity including glandular and stromal staining (graded as
0 =no reaction, 1=weak, 2=moderate and 3= strong staining)
and the percentage of positive-stained cells (0 = no positive,
1 =,25% of the cells, 2 = 25–50% of the cells, 3 = 51–75% of
the cells and 4=.75% of the cells) (Table 1). The IRS score
CRH Receptors in Endometriosis
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derived from both the glandular and the stromal staining of the
tissues.
Western Blot Analysis
100 mg of proteins were extracted from healthy women’s
eutopic endometrium (10 patients) and eutopic endometrium
and endometriotic tissue from endometriotic patients (16 patients),
placenta and myometrium followed by SDS-PAGE analysis in
10% acrylamide gel, and electrotransfer onto a nitrocellulose
membrane. The membrane was blocked in 5% skim milk powder
in 0.1% Tris-buffered saline/Tween for 20 min. The membrane
was then incubated with CRHRI (CRF-RI (V-14) goat polyclonal
antibody, Santa Cruz Biotechnology, Bergheimer, Germany) or
CRH RII (CRF-RII (C-15) goat polyclonal antibody, Santa Cruz
Biotechnology, Bergheimer, Germany) at a dilution of 1:1000,
followed by incubation with the peroxidase-conjugated donkey
antigoat IgG secondary antibody. GAPDH was used as a house
keeping gene. Protein extracts from placenta and myometrium
used as positive controls. The specificity of CRHR1 and CRHR2
polyclonal antibodies was confirmed by absorption with blocking
peptides sc-12381P and sc-20550P (Santa Cruz Biotechnology)
respectively. The blocking peptides for CRHR1 and CRHR2
antibody were mixed with the CRHR1 and CRHR2 antibodies
with a five-fold (by weight) excess of blocking peptides and
incubated overnight at 4uC. We had the same samples loaded
twice so that we could cut the nitrocelluse membrane in two lanes
having identical samples and one lane was incubated with the
polyclonal antibody and the other one with the blocked antibody
followed by followed by incubation with the peroxidase-conjugat-
ed donkey antigoat IgG secondary antibody. The lane which had
been incubated with the blocked peptide had its staining
disappeared was specific to the antibody. Band intensities of
protein of interest were normalized with band intensities of
GAPDH and expressed as arbitrary units (a.u.).
Evaluation and Statistical Analysis
Western blot and RT-PCR gel bands were analysed via image
analysis software (Scion Corporation, Release Beta 4.0.2, Freder-
ick, MD, USA). Statistical analysis was performed using the
unpaired two-tailed Student’s t-test. Any statistical difference at
p,0.05 was considered significant.
Results
1. CRH, UCN, CRHR1 and CRHR2 Expression in the
Endometriotic Sites
In order to verify the expression of the CRH, UCN, CRHR1
and CRHR2 in endometriotic lesions, we firstly tested the
expression of these transcripts by RT-PCR. Total RNA was
extracted from endometriotic tissues obtained from sixteen
patients with confirmed endometriosis. cDNA was synthesized
and was screened for the presence of both the ligand transcripts
(CRH and UCN) and their receptors’ transcripts (CRHR1b and
CRHR2a). Both CRH and UCN genes were found to be
transcribed in endometriotic tissues (Figure 1A, 1B). Interestingly,
both CRHR1b and CRHR2a were also present in endometriotic
tissues (Figure 1C, 1D). The above finding was further verified by
evaluating the protein expression levels of CRHR1 and CRHR2
receptors in endometriotic sites. Total protein extracts from
endometriotic tissues (obtained from 16 patients) were used for
CRHR1 and CRHR2 detection by western blot. As shown in
Figure 1E and 1F, both CRHR1 and CRHR2 are expressed in
endometriotic sites. Placental and myometrial tissue were used as
positive controls and GAPDH (Figure1G) as a house keeping gene
for Western blotting experiments.
2. High Expression Levels of CRHR1 and CRHR2 in Eutopic
Endometrium of Endometriotic Women Compared to
Eutopic Endometrium of Healthy Women
We then sought to evaluate and compare the expression of
CRHR1 and CRHR2 in eutopic endometrium of both healthy
and endometriotic women, at mRNA and protein level. mRNA
extracts of eutopic endometrium of healthy women (10 patients)
and endometriotic women (16 patients) used to perform RT-PCR
for both receptors. We found that CRHR1b and CRHR2a are
more highly expressed in eutopic endometrium of endometriotic
Table 1. IRS Score results.
Intensity of staining Percentage of positive cells IRS points-classification
0= no reaction 0 = no positive 0–1= negative
1 =weak staining 1 =,25% of the cells 2–3 =mild
2 =moderate staining 2 = 25–50% of the cells 4–8 =moderate
3 = strong staining 3 = 51–75% of the cells 9–12 = strongly positive
4 =.75% of the cells








0–1 =negative – – – –
2–3 =mild – – – –
4–8 =moderate 14/16 (87,5%) 9/16 (69,2%) 15/16 (93,75%) 11/16 (68,75%)
9–12 = strongly positive 2/16 (12,5%) 7/16 (43,75%) 1/16 (6,25%) 5/16 (31,25%)
We have found that 7/16(43,75%) ectopic endometrium samples showed strong CRH expression and 9/16(69,2%) ectopic endometrium samples showed moderate CRH
expression compared to 2/16(12,5%) eutopic endometrium samples of strong CRH expression and 14/16(87,5%) eutopic endometrium samples of moderate CRH
expression. Concerning the UCN expression in eutopic and ectopic endometium of the same patients, we have found that 5/16(31,25%) ectopic endometrium samples
showed strong UCN expression and 11/16(68,75%) ectopic endometrium samples showed moderate UCN expression compared to 1/16(6,25%) eutopic endometrium
samples of strong UCN expression and 15/16(93,75%) eutopic endometrium samples of moderate UCN expression.
doi:10.1371/journal.pone.0062313.t001
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women compared to eutopic endometrium of healthy women
(CRHR1b:1.20460.012 a.u. in endometriotic women vs
0.45860.020 a.u. in healthy women, which corresponds to 2.62
fold increase when eutopic endometrium of healthy women is set
as control, p,0.01; CRHR2a: 2.51860.012 a.u in endometriotic
women vs 1.89560.016a.u. in healthy women, which corresponds
to 1.32 fold increase when eutopic endometrium of healthy
women is set as control, p,0.01) ) (Figure 2A). This was further
corroborated at protein level (CRHR1: 2.92660.048 a.u in
endometriotic women vs 2.18760.034 a.u in healthy women,
which corresponds to 1.33 fold increase when eutopic endome-
trium of healthy women is set as control, p,0.01; CRHR2:
1.08760.021 a.u in endometriotic women vs 0.68560.017 a.u in
healthy women, which corresponds to 1.58 fold increase when
eutopic endometrium of healthy women is set as control, p,0.01)
by performing western blotting for CRHR1 and CRHR2
(Figure 2B) using protein extracts from the same material. Both
receptors showed an excessive expression in eutopic endometrium
of endometriotic women compared to healthy women. GAPDH
was used as a house keeping gene for both RT-PCR and Western
Blotting.
3. CRH, UCN, CRHR1b and CRHR2a Molecules are more
Abundant in Endometriotic Tissues Compared to the
Corresponding Eutopic Endometrium
We then compared the expression levels of CRH, UCN,
CRHR1b and CRHR2a in the endometriotic lesions and the
corresponding eutopic endometrium of the same women (16
patients). Total RNA was extracted from the eutopic and ectopic
endometrial samples (obtained from 16 patients), cDNA was
synthesized and was semi-quantitavely assessed for the presence of
CRH, UCN, CRHR1b and CRHR2a transcripts. We found that
in endometriotic foci CRH, UCN, CRHR1b and CRHR2a
mRNA expression was significantly higher compared to the
respective CRH, UCN, CRHR1b and CRHR2a mRNA content
in the eutopic endometrium of the same patients (CRH:
4.10160.582 a.u in ectopic vs 1.74160.580 a.u in eutopic
endometrium, 2.35 fold increase, p,0.01; UCN:
0.95660.136 a.u in ectopic vs 0.28260.075 a.u in eutopic
endometrium, 3.38 fold increase, p,0.01; CRHR1b:
1.13460.410 a.u in ectopic vs 0.18660.046 a.u in eutopic
endometrium, 6.07 fold increase, p,0.05; CRHR2a:
11.61561.837 a.u in ectopic vs 5.02361.723 a.u in eutopic
endometrium, 2.31 fold increase, p,0.01. In all cases eutopic
endometrium was set as control) (Figure 3a,A, 3b,A). The above
findings were further verified by evaluating the protein expression
levels in eutopic endometrium and endometriotic sites of the same
women. The signal of CRH and UCN in western blot analysis was
significantly low and could not be augmented because of the small
size of the protein molecules, thus formalin-fixed paraffin-
embedded tissue sections obtained from 16 patients were used
for the detection of CRH and UCN by immunohistochemistry.
According to IRS Score calculations (Table 1), CRH and UCN
were found to be expressed more intensely in ectopic endometri-
um (Figure 3a,B(D) and Figure 3a,B(E) respectively) compared to
eutopic endometrium (Figure 3a,B(A) and Figure 3a,B(B) re-
spectively) of the same women (Figure3b, B,) (CRH:
7.260.489 a.u in ectopic vs 6.160.378 a.u in eutopic endometri-
um, 1.18 fold increase, p,0.05; UCN: 6.960.458 a.u in ectopic vs
5.560.5 a.u in eutopic endometrium, 1.25 fold increase, p,0.05.
In both cases eutopic endometrium was set as control). In order to
identify the protein expression levels of the receptors CRHR1 and
CRHR2 between eutopic and ectopic endometrium, western blot
analysis was performed in 16 patients samples and showed that
both receptors are more highly expressed in ectopic than eutopic
endometrium of the same women (Figure 3a, C, Figure 3b, C)
(CRHR1: 3.32360.053 a.u in ectopic vs 2.92660.048 a.u in
eutopic endometrium, 1.13 fold increase, p,0.01; CRHR2:
2.65760.040 a.u in ectopic vs 1.08760.021a.u in eutopic
endometrium, 2.44 fold increase, p,0.01. In both cases eutopic
endometrium was set as control). GAPDH was used as a house
keeping gene for both RT-PCR and western blotting analysis.
Discussion
In this study, we show that CRH, UCN, CRHR1, CRHR2 and
the receptor subtypes CRHR1b and CRHR2a are expressed in
endometrium and endometriotic sites at mRNA and protein level.
This is the first time that the receptor subtype expression is
identified in endometriotic sites. Moreover, this study shows for
the first time that CRHR1 and CRHR2 are more highly expressed
in eutopic endometrium of endometriotic women compared to
endometrium of healthy women. Interestingly, we found that the
expression of CRH, UCN and their receptor subtypes, CRHR1
and CRHR2 is stronger in ectopic endometrium compared to that
in eutopic endometrium of women with endometriosis.
Endometriosis is a disease characterized by increased stress.
Both chronic pelvic pain and inflammation, commonly seen in
endometriosis, act as stressors, supporting a deregulation of
homeostasis towards a state of increased stress. Corticotropin
releasing hormone (CRH) is the main hormone of stress, being
expressed in different sites in the human body [11,12]. Since
endometriosis is a stress condition, it would be anticipated that
reproductive CRH may play a key-role in pathophysiology of
endometriosis, especially when pelvic pain or infertility are
associated with the disease.
CRH and UCN are neuropeptides expressed in several sites of
the female reproductive system including human endometrium
Figure 1. CRH, UCN, CRHR1 and CRHR2 expression in
endometriotic sites. A: CRH (413 bps), B: UCN(146 bps), C: CRHR1b
(554 bps) and D: CRHR2a (322 bps) mRNA expression and CRHR1
(55 kDa) and CRHR2 (55 kDa) protein expression in endometriotic
tissue(E) (1E, 1F respectively), having placental tissue (P) and myometrial
tissue (M) as positive control, negative sample(-), GAPDH(G) house
keeping gene. (representative data).
doi:10.1371/journal.pone.0062313.g001
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[11,12] and their highest mRNA expression is reached in the
secretory phase [27,13,28]. The main source of endometrial CRH
is epithelial cells whereas stromal cells express CRH only after the
decidualization process has begun [13,27,28,29]. CRH/UCN
could activate mast cells triggering thus inflammation and
adhesion formation, indicating an immune role of these molecules
in eutopic endometrium. Moreover, these neuropeptides have
been recently identified in endometriotic lesions [25,26]. Con-
cerning the CRH-related inflammatory profile of endometriosis,
progestins could inhibit the CRH-induced inflammation of
peritoneal cells in vitro [30]. Based on this published data, our
study firstly examined and confirmed the CRH and UCN mRNA
expression in endometriotic lesions of endometriotic women.
Given that CRH and UCN expression is mediated through
CRHR1 and CRHR2 and these receptors are expressed in several
sites of the female reproductive system [8], we investigated their
expression in endometriotic lesions. Despite the fact that CRH/
UCN have been implicated in endometriosis – a fact also verified
by our results, no data has been reported so far concerning the
expression of CRHR1 and CRHR2, the CRH and UCN
receptors. This is the first time a study shows that CRHR1 and
CRHR2 and specifically the CRHR1b and CRHR2a receptor
subtypes are expressed at mRNA and protein level, not only in the
endometrium but also at endometriotic sites indicating a potential
crucial role of CRH and UCN in endometriosis.
We compared the expression levels of CRHR1 and CRHR2 in
eutopic endometrium of endometriotic women with that in eutopic
endometrium of healthy women to further examine the implica-
tion of these molecules in endometriosis and the infertility profile
of endometriotic women. We show, for the first time, that CRHR1
and CRHR2 are significantly more expressed in the eutopic
endometrium of endometriotic women compared to eutopic
endometrium of healthy women. As previously described, CRH,
UCN and CRHR1 are expressed by human epithelial and stromal
endometrial cells. Endometrial stromal decidualization is a process
taking place in the luteal phase of the menstrual cycle, where CRH
expression is higher and leads to the induction of endometrial
stroma decidualization, stimulated by progesterone in a cAMP –
dependent manner [19,27,28,29,31,32]. Upon decidualization,
CRH inhibits the production of PGE2 and stimulates IL-1 and IL-
6 production in human endometrial stromal cells [24]. Endome-
triosis is an aseptic inflammatory process accompanied by altered
immune-related cell functions such as accumulation of macro-
phages and increased expression of growth factors, cytokines and
specifically interleukins IL-1 and IL-6 [4,5,33,34]. Additionally,
the expression of CRH in endometriosis has been correlated with
proinflammatory responses influencing thus innate and acquired
immune responses [35,36]. These data indicate that CRH and
UCN may be of importance in maintaining chronic inflammation
and thus local stress. Such stress could be further correlated to the
local symptoms often seen in endometriosis as increased infertility
rates, affected by modulation of the decidualization process and
improper function of endometrium in women with endometriosis.
A recent study [26] has proposed that there is an impaired CRH
and UCN expression in eutopic endometrium of endometriotic
women compared to healthy women endometrium. In our study
we evaluated the CRHR1 and CRHR2 mRNA and protein
expression levels in eutopic endometrium of endometriotic and
healthy women and we show for the first time that the expression
of both receptors is more elevated in eutopic endometrium of
endometriotic compared to that of healthy women. We could
hypothesize, as it has been shown by previous studies, that the
Figure 2. Higher CRHR1 and CRHR2 expression in eutopic endometrium of endometriotic women at an mRNA and protein level. A:
mRNA expression of CRHR1b(554 bps) and CRHR2a(322 bps) is higher in eutopic endometrium of endometriotic women(ee) compared to eutopic
endometrium of healthy women(he). B: protein expression of CRHR1 (55 kDa) and CRHR2 (55 kDa) is higher in ee compared to he. (**p,0.01)
(representative data).
doi:10.1371/journal.pone.0062313.g002
CRH Receptors in Endometriosis
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Figure 3. CRH, UCN, CRHR1 and CRHR2 excessive expression in endometriotic sites compared to eutopic endometrium of
endometriotic women. 3a) A: mRNA expression of CRH (413 bps), UCN (146 bps), CRHR1b (554 bps), CRHR2a (322 bps), GAPDH (483 bps) in
endometriotic tissue (e) and the corresponding eutopic endometrium (ee). B: Immunohistochemical expression of CRH(A,D) and UCN(B,E) in
eutopic(A,B) and ectopic endometrium(D,E). Both CRH and UCN are mainly expressed in endometriotic lesions.(C: negative eutopic endometrium, F:
negative ectopic endometrium). C: Western blot immunodetection of CRHR1 (55 KDa) and CRHR2 (55 KDa), in endometriotic tissue(e) and eutopic
endometrium(ee) of endometriotic women.GAPDH (37 kDa) used as a house keeping gene. CRH, UCN, CRHR1 and CRHR2a are significantly more
expressed at an mRNA and protein level in endometriotic tissue compared to the corresponding eutopic endometrium. (representative data). 3b)
Presentation of the normalized fold-increase of CRH, UCN, CRHR1 and CRHR2 expression in the study population at mRNA level(A) and protein
level(B: CRH and UCN protein levels, C: CRHR1 and CRHR2 protein levels) (*, p,0.05, **,p,0.01).
doi:10.1371/journal.pone.0062313.g003
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impaired expression of CRH and UCN in eutopic endometrium of
endometriotic women [26] and the reduced capacity of CRH and
UCN to induce in vitro decidualization of endometriotic women
stromal cells [26] may contribute to further expression of their
receptor to keep a proper function of endometrium in endome-
triotic women. Unidentified endometrial defects in endometriosis
could also affect the expression of CRH and UCN resulting in
increased expression of CRHR1 and CRHR2 acting as a regula-
tory mechanism to compensate for the reduced efficiency of
proper endometrial function of endometriotic women. Despite the
fact that little is known so far for the expression patterns of the
CRH receptors in intrauterine tissue, these findings could be in
cohort with other studies showning that long term stimulation of
pituitary [37] and myometrial cells [38].with CRH can down-
regulate its own CRHR1 receptor. Further studies are needed to
further elucidate this controversial expression pattern between
CRH, UCN and their receptors expression in eutopic endome-
trium of endometriotic women.
CRH and UCN exert an important role not only in
decidualization but also in blastocyst implantation [31]. Invasion
of the blastocyst in the decidualized endometrium needs to take
place for a successful embryo implantation [22]. CRH is produced
by maternal decidual cells and embryonic trophoblast and is
implicated in the maternal- blastoyst immune ‘‘cross-talk’’ by
stimulating the expression of FasL in invasive extravillous
trophoblast and maternal decidual cells and by increasing the
apoptosis of T-lymphocytes through FasL induction. Thus the
graft vs host reaction from the maternal immune system to the
fetus is prevented and this is mediated through CRHR1 [32].
Studies in mice models have also shown that blocking of CRHR1
results in implantation dysfunctions [39] reinforcing thus the role
of CRH in embryo implantation. Our findings showing that
CRHR1 and CRHR2 are more abundantly expressed in eutopic
endometrium of endometriotic women might explain the fact that
endometriotic women can be fertile, characterised as hypofertile
but not completely sterile, as there is excessive expression of
CRHR1 and CRHR2 overcoming thus the low levels of CRH and
UCN leading to implantation.
We also compared the expression of CRH, UCN, CRHR1 and
CRHR2 in ectopic endometrium of endometriotic women
compared to their eutopic endometrium. For the first time we
found that all these molecules are more highly expressed in ectopic
rather than eutopic endometrium of the same patients at mRNA
and protein level. The fact that these molecules are more highly
expressed in ectopic endometrium indicate that their function
outside the uterus might be strengthened, which may potentially
contribute to implantation and pregnancy maintenance problems
of women with endometriosis.
Given also that high levels of stress are correlated with the
progression of endometriosis [40] combined with the fact that
CRH is activated by high levels of stress [6,7,30], our results may
explain the neuroendocrine vicious circle of stress, mediated by
CRH and UCN which is expected to maintain a chronic
inflammatory profile as well as infertility.
In conclusion, the current study shows for the first time that not
only CRH and UCN but also CRHR1 and CRHR2 are expressed
in endometriotic lesions and that CRH, UCN, CRHR1 and
CRHR2 are significantly more abundant in endometriotic lesions
than the corresponding eutopic endometrium of endometriotic
women. We also show that these receptors are more highly
expressed in eutopic endometrium of endometriotic women
compared to healthy individuals. Our findings point to a new
inflammatory modulator pathway in which CRH, UCN, CRHR1
and CRHR2 are involved acting by an autocrine/paracrine
pathway in eutopic and ectopic endometrium potentially affecting
the pathogenesis of this benign disease and infertility profile of
endometriotic women. These results suggest that a new therapeu-
tic intervention could potentially based on blockage of CRH,
UCN and their receptors leading to the improvement of the
quality of endometriotic women’s life. Further mechanistic
experiments and experiments on appropriate models needs to be
done in order to clarify this role and highlight a potential use of
anti-CRHR1 and anti-CRHR2 treatment in endometriosis.
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